文献速递淋巴瘤

N-甲基化血小板反应蛋白-1衍生肽靶向治疗慢性淋巴细胞白血病并克服耐药

Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.
PubMed 文献 · Blood Adv · 2019-01-01

本研究探讨N-甲基化血小板反应蛋白-1衍生肽对慢性淋巴细胞白血病(CLL)细胞的杀伤作用。PKT16为最优肽,可选择性清除恶性CLL细胞(包括高危遗传学异常者), sparing正常造血前体,并在CLL异种移植小鼠模型中降低肿瘤负荷。PKT16通过Gαi蛋白激活、cAMP/PKA下降、胞内Ca2+失调引发线粒体损伤和caspase非依赖性程序性坏死,并诱导免疫原性细胞死亡标志。

要点

  • PKT16可杀伤高危遗传学异常(del11q、del17p、2p gain、复杂核型)的CLL细胞。
  • PKT16不伤害正常造血前体细胞,并在CLL异种移植小鼠中降低肿瘤负荷。
  • PKT16诱导caspase非依赖性程序性坏死和免疫原性细胞死亡标志。

核心结论

  • N-甲基化TSP-1衍生肽PKT16能有效杀伤恶性CLL细胞并克服高危遗传学异常相关耐药。

研究设计与样本

  • 体外研究结合CLL异种移植小鼠模型,评估N-甲基化TSP-1衍生肽对CLL细胞的杀伤作用。

主要发现

  • PKT16可消除白血病细胞而保留非肿瘤细胞(包括造血前体),并降低CLL异种移植小鼠的体内肿瘤负荷。
  • PKT16的细胞毒性效率优于先前描述的TSP-1衍生探针PKHB1。
  • PKT16引发caspase非依赖性程序性坏死,不同于坏死性凋亡或铁死亡,涉及胞内Ca2+失调导致线粒体损伤和细胞周期阻滞。
  • Gαi蛋白激活及随后的cAMP水平和PKA活性下降调控该细胞毒性级联。
  • PKT16诱导免疫原性细胞死亡标志,包括钙网蛋白膜暴露及ATP和HMGB1释放。

临床怎么用

  • PKT16可能成为针对CLL(包括高危遗传学异常患者)的新型治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL), the most common adulthood leukemia in Western countries, is a very heterogeneous disease characterized by a peripheral accumulation of abnormal CD5+ B lymphocytes in the immune system. Despite new therapeutic developments, there remains an unmet medical need for CLL. Here, we demonstrate that the use of N-methylated thrombospondin-1 (TSP-1)-derived peptides is an efficient way to kill the malignant CLL cells, including those from high-risk individuals with poor clinical prognosis, del11q, del17p, 2p gain, or complex karyotype. PKT16, our hit N-methylated peptide, triggers the elimination of the leukemic cells, sparing the nontumor cells, including the hematopoietic precursors, and reduces the in vivo tumor burden of a CLL-xenograft mice model. A complementary analysis underscores the improved cytotoxic efficiency of PKT16 compared with the previously described TSP-1-derived probes, such as PKHB1. PKT16 elicits an original caspase-independent programmed necrotic mode of cell death, different from necroptosis or ferroptosis, implicating an intracellular Ca2+ deregulation that provokes mitochondrial damage, cell cycle arrest, and the specific death of the malignant CLL cells. The activation of the Gαi proteins and the subsequent drop of cyclic adenosine monophosphate levels and protein kinase A activity regulate this cytotoxic cascade. Remarkably, PKT16 induces the molecular hallmarks of immunogenic cell death, as defined by the calreticulin plasma membrane exposure and the release of adenosine triphosphate and high-mobility group box 1 protein from the dying CLL cells. Thus, PKT16 appears to be able to stimulate an anticancer in vivo immune response. Collectively, our results pave the way toward the development of an efficient strategy against CLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pramil E, Herbi Bastian L, Denèfle T, et al. Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance. Blood Adv. 2019. PMID: 31648314. doi:10.1182/bloodadvances.2019000350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。